Antigenic Protein Conjugates and Process for Preparing Same

• US 20100151490A1
• Filed: 02/25/2010
• Published: 06/17/2010
• Est. Priority Date: 09/01/2006
• Status: Abandoned Application

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Blincko, Stuart J., Rodgers, Brian C., Blackwell, Deborah A., Doran, Emma J.
• Application Number:
  US12/712,564
• Publication Number:
  US 20100151490A1
• Time in Patent Office: Days
• US Class Current: 435/7.100
• CPC Class Codes: A61K 47/646 the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
• CPC Class Codes: G01N 33/531 Production of immunochemical test materials
• CPC Class Codes: G01N 33/532 Production of labelled immunochemicals
• CPC Class Codes: G01N 33/5767 non-A, non-B hepatitis

Abstract

An improved process for the preparation of antigenic protein conjugates is provided. The conjugates preferably are formed through reaction with one or more free sulfhydryl groups in the antigenic protein. The process of the present invention preferably employs a trialkylphosphine as the reducing agent and allows for reduction of disulfide bonds in the antigenic protein and conjugation with a conjugate moiety, preferably in a single reaction vessel (i.e. “in situ”) because the process optimally does not require the removal of the reducing agent before subsequent addition of the sulfhydryl reactive agent. Antigenic protein conjugates prepared by the in situ process and their use in diagnostic immunoassays are also provided.

Claims

1. A process for preparing an antigenic protein conjugate comprising the steps of:

(a) contacting an antigenic protein comprising one or more disulfide bonds with a trialkylphosphine under conditions that allow reduction of at least one of said one or more disulfide bonds to provide a reduced antigenic protein comprising at least a pair of sulfhydryl residues, and

(b) contacting said reduced antigenic protein with a sulfhydryl reactive reagent comprising a conjugate moiety and a thiol-reactive functionality under conditions that allow reaction of at least one of said sulfhydryl residues with the sulfhydryl reactive reagent to form said antigenic protein conjugate.

2. The process of claim 1, wherein said trialkylphosphine is selected from the group consisting of tris(2-carboxyethyl)phosphine, tris(2-cyanoethyl)phosphine and tributylphosphine.

3. The process of claim 1, wherein said antigenic protein is a viral protein.

4. The process of claim 1, wherein said antigenic protein is a hepatitis C virus protein or a human immunodeficiency virus protein.

5. The process of claim 1, wherein said antigenic protein is a hepatitis C virus protein.

6. The process of claim 5, wherein said hepatitis C virus protein is non-structural protein NS3.

7. The process of claim 1, wherein said conjugate moiety is a detectable label.

8. The process of claim 1, wherein said conjugate moiety is an enzyme.

9. The process of claim 8, wherein said enzyme is horseradish peroxidase.

10. The process of claim 1, wherein said thiol-reactive functionality is a maleimide or an iodoacetamide.

11. The process of claim 1, wherein said thiol-reactive functionality is a maleimide.

12. An antigenic protein conjugate prepared by a process comprising the steps of:

(a) contacting an antigenic protein comprising one or more disulfide bonds with a trialkylphosphine under conditions that allow reduction of at least one of said one or more disulfide bonds to provide a reduced antigenic protein comprising at least a pair of sulfhydryl residues, and

(b) contacting said reduced antigenic protein with a sulfhydryl reactive reagent comprising a conjugate moiety and a thiol-reactive functionality under conditions that allow reaction of at least one of said sulfhydryl residues with the sulfhydryl reactive reagent to form said antigenic protein conjugate.

13. A method for detecting antibodies to an antigenic protein in a sample comprising:

(i) contacting the sample with an antigenic protein conjugate according to claim 12 under conditions that allow the formation of an antibody;

antigenic protein conjugate complex, and

(ii) detecting any antibody;

antigenic protein conjugate complex formed in step (i).